Skip to main content
Atrial fibrillation associated with heart failure treated by a 2-lead CRT-DX system (BIO-AffectDX): Study design and clinical protocol.
- Author(s): Hsu, Jonathan C;
- Hesselson, Aaron B;
- Liang, Jackson J;
- Mountantonakis, Stavros;
- David, Gregory T;
- Costea, Alexandru
- et al.
Published Web Locationhttps://doi.org/10.1016/j.hroo.2021.10.001
BackgroundEvidence to support use of cardiac resynchronization therapy (CRT) among patients with both heart failure (HF) and atrial fibrillation (AF) is largely limited to retrospective or post hoc subanalyses. Data from a prospectively enrolled and contemporary cohort are needed.
ObjectiveWe aim to better characterize the changes from baseline in HF patients with concomitant AF subsequently implanted with a 2-lead CRT-DX system capable of sensing in the atrium, aggregating diagnostics, and delivering CRT therapy. The primary objective of this study is to evaluate the percentage of all HF subjects with an improvement in a clinical composite score from pre-CRT implant to 12 months.
MethodsThe study is a US-based, prospective, observational multicenter clinical trial conducted at up to 50 sites and enrolling approximately 400 subjects with a follow-up period of 1 year. Multiple subject assessments, atrial rhythm status, and device interrogation will be collected at follow-up visits occurring at 3, 6, and 12 months postimplant.
ResultsA Clinical Events Committee will adjudicate subject HF events, arrhythmia events, death events, and all device-classified ventricular tachycardia and ventricular fibrillation episodes with treatment that are collected throughout the follow-up period. Their decisions are based on independent physician review of the data from sites and device interrogation.
ConclusionThe BIO-AffectDX study aims to provide further insight into the expected outcomes from CRT treatment in patients with HF and AF.
For improved accessibility of PDF content, download the file to your device.